The First Placebo-Controlled Trial of a Special Butterbur Root Extract for the Prevention of Migraine: Reanalysis of Efficacy Criteria
- 1 March 2004
- journal article
- clinical trial
- Published by S. Karger AG in European Neurology
- Vol. 51 (2), 89-97
- https://doi.org/10.1159/000076535
Abstract
This is an independent reanalysis of a randomised, placebo-controlled parallel-group study on the efficacy and tolerability of a special butterbur root extract (Petadolex®) for the prophylaxis of migraine. The original protocol and analysis had a number of major shortcomings. In order to follow regulatory requirements, an independent reanalysis of the original data was performed. Following a 4-week baseline phase, 33 patients were randomised to treatment with two capsules 25 mg butterbur twice a day and 27 to placebo. The mean attack frequency per month decreased from 3.4 at baseline to 1.8 after 3 months (p = 0.0024) in the verum group and from 2.9 to 2.6 in the placebo group (n.s.). The responder rate (improvement of migraine frequency ≧50%) was 45% in the verum group and 15% in the placebo group. Butterbur was well tolerated. This small trial indicates that butterbur may be effective in the prophylaxis of migraine.Keywords
This publication has 5 references indexed in Scilit:
- Mechanisms of Relaxant Action of S-Petasin and S-Isopetasin, Sesquiterpenes of Petasites formosanus, in Isolated Guinea Pig TracheaPlanta Medica, 2001
- Differential inhibition of inflammatory effector functions by petasin, isopetasin and neopetasin in human eosinophilsClinical and Experimental Allergy, 2001
- Role of petasin in the potential anti-inflammatory activity of a plant extract of petasites hybridusBiochemical Pharmacology, 2001
- Relaxant Effects of Petasins in Isolated Guinea Pig Trachea and Their Structure-Activity RelationshipsPlanta Medica, 2000
- Petasites hybridus: A tool for interdisciplinary research in phytotherapyPharmaceutica Acta Helvetiae, 1998